Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The average time of dilation lasts three to eight hours
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Application based on results from the TROPION-Breast01 Phase III trial
Establishment of 220 smart classrooms across Uttar Pradesh, Uttarakhand, and Himachal Pradesh
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Subscribe To Our Newsletter & Stay Updated